Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.2.117

Crystal Forms of Ziprasidone  

Youn, Mi-Hee (Department of Chemistry, Duksung Women's University)
Bang, Hyo-Chun (Department of Chemistry, Duksung Women's University)
Sohn, Young-Taek (College of Pharmacy, Duksung Women's University)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.2, 2009 , pp. 117-120 More about this Journal
Abstract
Two crystal forms of ziprasidone have been isolated by recrystallization from different organic solvents and characterized by differential scanning calorimetry, powder X-ray diffractometry and thermogravimetric analysis. It was confirmed that Form 2 has the same crystal structure as Form 1.
Keywords
Ziprasidone; Crystal form; DSC; PXRD; TGA;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 J. Bernstein, Polymorphism and the investigation of structure-property relations in organic solids, Int. Union Crystallogr. Crystallogr. Symp., 4 (Org. Cryst. Chem.), 6-26 (1991).
2 F. Bayard, C. Decoret and J. Royer, Structural aspects of polymorphism and phase transition in organic molecular crystals, Stud. Phys. Theor. Chem., 69 (Struct. Prop. Mol. Cryst.), 211-234 (1990).
3 N. Kaneniwa, M. Otsuka, T. Yamaguchi, T. Hayashi, K. Hayashi, T. Matsumoto, N. Watari and O. Unezawa,Preparation of polymorphs of some crystalline drug powders, Funsai, 33, 30-41 (1989).
4 E. F. Fiese and T.A. Hagen, Preformulation : In Theory and Practice of Industrial Pharmacy, L. Lachman, H. A. Lieberman and J. L. Kanig (Ed.), Third Edition, Lea and Febiger, Philadelphia, pp 176-181 (1986)
5 H. G. Brittain and D. J. W. Grant, Effects of polymorphism and solid-state solvation on solubility and dissolution rate : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 279-330 (1999)
6 Y. T. Sohn, Crystal forms of an angiotensin II receptor antagonist BR-A657, J. Therm. Anal. Cal., 89(3), 799-802 (2007).   DOI   ScienceOn
7 Y. T. Sohn, Effect of crystal form on bioavailability, J. Kor. Pharm. Sci., 34, 443-452 (2004).   과학기술학회마을
8 W. C. Kind, P. Varlashkin and C. Li, The applicability of powder x-ray diffraction to the quantification of drug substance polymorphs using a model organic system, Powder Diffr., 8, 180-187 (1993).   DOI
9 M. R. Caira, M. Zanol, T. Peveri, A. Gazzaniga and F. Giordano, Structural characterization of two polymorphic forms of piroxicam pivalate, J. Pharm. Sci., 87, 1608-1614 (1998).   DOI   ScienceOn
10 A. Burger and K. T. Koller, Polymorphism and pseudopolymorphism on nifedifine, Sci. Pharm., 64, (1996).
11 A. David, E. Balogh, G. Csoka and I. Racz, Methodological aspects of examination of the polymorphism of vincristine sulfate, Sci. Pharm., 64, 311-318 (1996).
12 E. A. Lee and Y. T. Sohn, Crystal forms of a capsaicin derivative analgesic DA-5018, J. Therm. Anal. Cal., 93(3), 871-874 (2008).   DOI   ScienceOn
13 Y. T. Sohn and B. Y. Park, Characterization of the physicochemical properties of KR-31378, Arch. Pharm. Res., 26, 526-531 (2003).   DOI   ScienceOn
14 Y. T. Sohn and H. O. Seo, Crystal Forms of Ketorolac, Arch. Pharm. Res., 27, 357-360 (2004).   DOI   ScienceOn
15 A. Bauer-Brandl and Y. T. Sohn, Crystal modifications of cimetidine: Characterization and evaluation for manufacturing of dosage forms, Eur. J. Pharm. Biopharm., 40 (Suppl.), (1994).
16 Y. T. Sohn, J. K. Lee and W. B. Im, Polymorphism of clarithromycin, Arch. Pharm. Res., 23, 381-384 (2000).   DOI   ScienceOn
17 Y. T. Sohn and S. Y. Kim, Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids, Arch.Pharm. Res., 25, 556-559 (2002).   DOI   ScienceOn
18 Y. T. Sohn and S. H. Park, Crystal Forms of Cephradine, Arch. Pharm. Res., 29, 178-182 (2006).   DOI   ScienceOn
19 Y. T. Sohn, Effect of polymorphism on bioavailability of amoxycillin, Yakhak Hoeji., 39, 438-443 (1995).
20 A. Burger, Zur Interpretation von Polymorphie-untersuchungen, Acta Pharm. Technol., 28, 1-20 (1982).
21 J. Haleblian and W. McCrone, Pharmaceutical applications of polymorphism, J. Pharm. Sci., 58, (1969).   DOI
22 H. G. Brittain, Methods for the characterization of polymorphs and sovates : In Polymorphism in Pharmaceutical Solids, H. G. Brittain (Ed.), Marcel Dekker Inc., New York·Basel, pp 227-278 (1999)
23 B. D. Sharma, Allotropes and polymorphs, J. Chem. Educ., 64, 404-407 (1987).   DOI
24 J. Bernstein, Conformational polymorphism, Stud. Org. Chem. (Amsterdam), 32(Org. Solid Statd Chem.), 471-518 (1987).
25 M. Kitamura, Polymorphism in crystallization, Kagaku kogaku, 55, 263-264 (1991).
26 Y. T. Sohn and Y. H. Lee., Polymorphism of Doxazocin mesylate, Arch. Pharm. Res., 28, 732-737 (2005).   DOI   ScienceOn
27 Y. T. Sohn and S. H. Kim, Polymorphism and pseudopolymorphism of acyclovir, Arch. Pharm. Res., 31, 231-234 (2008).   DOI   ScienceOn